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subjects without a cap: HR = 0.75 for $750 (95% CI:
0.70–0.80); HR = 0.80 for $500 (95% CI: 0.75–0.85); HR =
0.81 for $250 (95% CI: 0.77–0.85). CONCLUSIONS: These
preliminary analyses indicate that patients with annual drug
beneﬁt caps appear to anticipate exceeding the beneﬁt limit, and
reduce their drug consumption prior to reaching the cap amount.
Further research is needed to assess how patients reduce their
drug consumption and the clinical and economic impact.
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OBJECTIVE: This paper compares the prices of top selling
generic drugs in Canada with prices for comparable generics in
the United States (updating a 2002 study). METHODS: We 
compared manufacturer prices of 21 top selling (in 2004) generic
prescription medicines in Canada that were marketed in both
Canada and the US. Sources of Canadian prices included gov-
ernment reimbursed prices for Quebec, British Columbia and
Saskatchewan. US prices were sourced from the Federal Supply
Schedule (FSS) and three state Medicaid program Maximum
Allowable Cost (MAC) lists. The prices of a subset of 11 drugs
that appeared in both studies were compared to investigate
trends. RESULTS: Of the 21 leading generic drugs, 20 had higher
prices in Canada. Canadian prices were higher than US prices on
all measures: Mean: +238%; Weighted Mean: +259%, Median
+128%. If Canadians could access FSS prices for the 21 sample
drugs, annual savings would exceed C$440 million. If the price
differences observed are extrapolated to all generic drugs sold 
in Canada, annual savings could exceed C$1 billion. Canadian
prices were also higher than state Medicaid MAC prices: Mean:
+44%; Median: +15%. When comparing the 11 drugs that 
were included on both studies, a clear trend emerges: US prices
have decreased 31% since 2001, while Canadian prices have
remained stable. CONCLUSIONS: US prices of top-selling
generics are lower than those in Canada and the price gap is
widening. US generic prices are now on average 238% lower
than those in Canada compared to 155% in 2001. Provincial
government policies that establish Canadian generic prices at a
percentage of branded products are one of the factors that
appear to discourage price competition. Unlike Canada, US
generic prices typically fall over time as more manufacturers
enter the market and compete for government contracts and 
formulary listings.
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OBJECTIVE: To evaluate the role of pharmacoeconomics in the
Greek pharmaceutical environment. METHODS: The existing
pharmaceutical reimbursement system in Greece and the pro-
posal for the new pharmaceutical policy, announced in Novem-
ber 2004 by the Greek Ministry of Health and Social Solidarity
were examined. RESULTS: The current reimbursement system
in Greece consists of a positive reimbursement list. The main cri-
terion for a product to be accepted for reimbursement is its daily
drug cost in comparison to the average drug cost of the thera-
peutic cluster to which it belongs. Nevertheless, other factors are
also taken into account in order to approve reimbursement, such
as the non-mandatory submission of pharmacoeconomic studies,
even though their role in a positive or negative reimbursement
decision is not clariﬁed. The new system announced by the Min-
istry states that it plans to abolish the reimbursement list. In the
place of the current reimbursement system it proposes, among
other measures that aim to contain costs and alleviate patient
burden, the implementation of a rebate system where drugs are
grouped into therapeutic clusters and a reference price is calcu-
lated for each cluster. Pharmaceutical companies will return the
weighted difference between their products’ price and the refer-
ence price to social insurance organizations. The proposal states
that rebate levels can be adjusted based on pharmacoeconomic
evidence in order to reward cost-effective therapies. Addition-
ally, the proposal announces the establishment of a Health care
Technology Evaluation Agency that will evaluate technologies
and produce guidelines based on evidence based medicine and
cost-effectiveness parameters. This Agency will also evaluate
pharmaceconomic evidence in cases where there is a need to
adjust rebate levels for speciﬁc products. CONCLUSIONS: At
present, pharmacoeconomics play a limited role in the reim-
bursement of pharmaceuticals in Greece. The new pharmaceuti-
cal policy proposal reinforces the role of pharmacoeconomics in
Greece, which is a welcome development.
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OBJECTIVES: To cut the escalating costs for pharmaceuticals
the responsibility for costs of outpatient prescription drugs was
decentralized from the government in Sweden to the county
councils in 2002. The study aims to investigate if the introduc-
tion of decentralized responsibility had an impact on the phar-
maceutical cost development in Sweden. METHODS: Monthly
sales data, on the pharmaceutical beneﬁts scheme, PBS, to each
county council was obtained for the period January 2000 to May
2005. Interrupted time series analysis was used to investigate 
the effects of the introduction of decentralized responsibility on
pharmaceutical costs in both total sales and sales of prescription
drugs within total and within the PBS. This was investigated both
on country level and with comparisons between county councils
with different budget models for the decentralized responsibility.
The investigation is continuing. RESULTS: Analyses show 
that there was no signiﬁcant change in the cost trend associated
with the introduction of decentralized responsibility for costs of
outpatient prescription drugs. The county councils’ costs of 
prescribed drugs covered by the PBS were on three levels;
€19.5/inhabitant in 2000 and €23.9/inhabitant in May 2005, the
second €15.7/inhabitant in 2000 and €19.5/inhabitant in May
2005 and the third €3.6/inhabitant in 2000 and €6.0/inhabitant
in May 2005. All county councils remained on the same level
throughout the study period. The budget model for outpatient
prescription drugs had no impact on the level of costs. When
considering total drug expenditures including inpatient drug
costs the three segments diminish and all county councils 
are gathered between €21.7–26.0/inhabitant in 2000 and
€28.2–34.7/inhabitant in May 2005. CONCLUSIONS: Pharma-
ceutical costs increased despite the introduction of decentralized
cost responsibility for drugs in outpatient care. The budget
models had no clear impact on the cost trend.
